23 results on '"Virginie Grouthier"'
Search Results
2. ICAM1 expression by the microvasculature impairs capillary perfusion which compromises hind limb ischemia recovery in diabetic mice
- Author
-
Ninon Foussard, Paul Rouault, Lauriane Cornuault, Célia Bourguignon, Virginie Grouthier, Candice Chapouly, Alain-Pierre Gadeau, Thierry Couffinhal, and Marie-Ange Renault
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
3. Thrombosis in the coronary microvasculature may be responsible for impaired cardiac relaxation and diastolic dysfunction
- Author
-
Paul Rouault, Lauriane Cornuault, Ninon Foussard, Célia Bourguignon, Virginie Grouthier, Frank Choveau, David Benoist, Alain-Pierre Gadeau, Thierry Couffinhal, and Marie-Ange Renault
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
4. Cardiac pericytes may contribute to heart disease
- Author
-
Célia Bourguignon, Lauriane Cornuault, Ninon Foussard, Paul Rouault, Virginie Grouthier, Candice Chapouly, Alain-Pierre Gadeau, Thierry Couffinhal, and Marie-Ange Renault
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
5. Diastolic dysfunction is associated with cardiac small vessel disease in ovariectomized females but not in males
- Author
-
Lauriane Cornuault, Virginie Grouthier, Paul Rouault, Célia Bourguignon, Ninon Foussard, Candice Chapouly, Alain-Pierre Gadeau, Thierry Couffinhal, and Marie-Ange Renault
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2023
6. About a case of macro-FSH analytical interference
- Author
-
Claire Guibet, Alizée Violin, Jean-Benoît Corcuff, Agnès Georges, Julie Brossaud, Virginie Grouthier, and Cindy Lauro
- Subjects
endocrine system ,Adolescent ,media_common.quotation_subject ,Physiology ,Antibodies, Heterophile ,Interference (genetic) ,Mice ,Animals ,Humans ,Medicine ,Pathological ,Menstrual cycle ,Autoantibodies ,media_common ,biology ,business.industry ,Ovarian failure ,Autoantibody ,General Medicine ,medicine.disease ,University hospital ,Premature ovarian failure ,biology.protein ,Female ,Follicle Stimulating Hormone ,Antibody ,business - Abstract
An 18-year-old woman was referred by her GP to the endocrinology department of the University Hospital of Bordeaux on suspicion of premature ovarian failure because of a disorder of the menstrual cycle and pathological results of biological exploration of the gonadotropic axis. Repeatedly-found elevated concentrations of FSH contrasted with a normal concentration of LH leading to a hypothesis of ovarian failure. However, different investigations favoured an analytical interference. The presence of heterophilic antibodies or anti-mouse antibodies (HAMA) was unlikely but, finally, a complex combining FSH and autoantibody (called macro-FSH) was evidenced.
- Published
- 2021
7. Whole exome sequencing in a cohort of familial premature ovarian insufficiency cases reveals a broad array of pathogenic or likely pathogenic variants in 50% of families
- Author
-
Alexandre Rouen, Eli Rogers, Véronique Kerlan, Brigitte Delemer, Sophie Catteau-Jonard, Yves Reznik, Anne Gompel, Isabelle Cedrin, Anne-Marie Guedj, Virginie Grouthier, Thierry Brue, Catherine Pienkowski, Anne Bachelot, Sandra Chantot-Bastaraud, Alexandra Rousseau, Tabassome Simon, Esther Kott, Jean-Pierre Siffroi, Philippe Touraine, Sophie Christin-Maitre, Maladies génétiques d'expression pédiatrique (U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hopital port Royal, Partenaires INRAE, Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Marseille Maladies Rares (MarMaRa), Aix Marseille Université (AMU), Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM], CHU Saint-Antoine [AP-HP], and Programme Hospitalier de Recherche Clinique AOM08084, NI07022 FAMIOP
- Subjects
premature ovarian insufficiency ,Genes in POI ,[SDV]Life Sciences [q-bio] ,Menopause, Premature ,Obstetrics and Gynecology ,Primary Ovarian Insufficiency ,hypergonadotropic hypogonadism ,whole exome sequencing ,Cohort Studies ,Fragile X Mental Retardation Protein ,Cross-Sectional Studies ,primary amenorrhea ,Reproductive Medicine ,Exome Sequencing ,Humans ,Female - Abstract
International audience; Objective: To study the diagnostic yield, including variants in genes yet to be incriminated, of whole exome sequencing (WES) in familial cases of premature ovarian insufficiency (POI). Design: Cross-sectional study. Setting: Endocrinology and reproductive medicine teaching hospital departments. Patients: Familial POI cases were recruited as part of a nationwide multicentric cohort. A total of 36 index cases in 36 different families were studied. Fifty-two relatives were available, including 25 with POI and 27 affected who were nonaffected. Karyotype analysis, FMR1 screening, single nucleotide polymorphism array analysis, and WES were performed in all subjects. Interventions: None. Main Outcome Measures: The primary outcome was a molecular etiology, as diagnosed by karyotype, FMR1 screening, single nucleotide polymorphism array, and WES. Results: A likely molecular etiology (pathogenic or likely pathogenic variant) was identified in 18 of 36 index cases (50% diagnostic yield). In 12 families, we found a pathogenic or likely pathogenic variant in a gene previously incriminated in POI, and in 6 families, we found a pathogenic or likely pathogenic variant in new candidate genes. Most of the variants identified were located in genes involved in cell division and meiosis (n = 11) or DNA repair (n = 4). Conclusions: The genetic etiologic diagnosis in POI allows for genetic familial counseling, anticipated pregnancy planning, and ovarian tissue preservation or oocyte preservation. Identifying new genes may lead to future development of therapeutics in reproduction based on disrupted molecular pathways. Clinical Trial Registration Number: NCT 01177891. ((C) 2021 by American Society for Reproductive Medicine.) El resumen esta disponible en Espanol al final del articulo.
- Published
- 2022
8. [Impact of combined oral contraceptives and spironolactone on hirsutism and quality of life]
- Author
-
Nina, Lefoulon, Emmanuelle, Begon, Marie, Perrissin-Fabert, Virginie, Grouthier, Claude, Hocke, and Valérie, Bernard
- Subjects
Contraceptives, Oral, Combined ,Hirsutism ,Quality of Life ,Humans ,Female ,Spironolactone ,Retrospective Studies - Abstract
Combined oral contraceptives (COC) and spironolactone are the first and second-line treatments of mild hirsutism, since the use of cyproterone acetate was restricted to the treatment of severe hirsutism by the French guidelines for hyperandrogenism published in May 2020. Because spironolactone was until now barely used in France, the aim of this study was to evaluate the indication, efficacy and impact on quality of life of COC and spironolactone treatments on mild hirsutism in non-menopausal women.This retrospective monocentric study was conducted between June 2020 and October 2021. It included patients with mild hirsutism who received a prescription of COC or/and spironolactone. Modified Ferriman and Gallwey score (FGm) was performed by clinicians and self-rated by patients during the follow-up. Hirsutism-related quality of life was assessed using the Dermatology Life Quality Index (DLQI) and a visual analog scale.A total of 44 patients were included, but only 30 patients received the treatment for 6 months. 70% of patients were free of side effects. Clinically we observed a decrease of 26% in the FGm score rated by clinicians and patients after 6 months of treatment (P0,01). This was not correlated with an improvement in quality of life.The data collected showed the clinical efficacy of both COC and spironolactone in the treatment of mild hirsutism. These two treatments were well-tolerated. However, the quality of life scores did not improve after 6 months. These treatments should be evaluated after a longer period.
- Published
- 2022
9. Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias
- Author
-
Xavier Waintraub, Joe-Elie Salem, Melissa Y.Y. Moey, Christian Funck-Brentano, Estelle Gandjbakhch, Anne Bachelot, Virginie Grouthier, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], East Carolina University [Greenville] (ECU), University of North Carolina System (UNC), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de référence des maladies endocriniennes rares de la croissance et du développement [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre des Pathologies gynécologiques Rares [CHU Pitié-Salpêtrière], Service d’endocrinologie et médecine de la reproduction [CHU Pitié-Salpêtrière], Vanderbilt University [Nashville], Gestionnaire, Hal Sorbonne Université, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Service d'Endocrinologie et Médecine de la Reproduction [CHU Pitié-Salpêtrière]
- Subjects
Male ,[SDV]Life Sciences [q-bio] ,Review ,030204 cardiovascular system & hematology ,lcsh:Chemistry ,0302 clinical medicine ,Risk Factors ,atrial fibrillation ,030212 general & internal medicine ,Gonadal Steroid Hormones ,lcsh:QH301-705.5 ,Spectroscopy ,Brugada syndrome ,Brugada Syndrome ,Sex Characteristics ,Atrial fibrillation ,General Medicine ,3. Good health ,Computer Science Applications ,[SDV] Life Sciences [q-bio] ,Long QT Syndrome ,Cardiology ,cardiovascular system ,Hormonal therapy ,Female ,medicine.medical_specialty ,medicine.drug_class ,QT interval ,Catalysis ,Inorganic Chemistry ,03 medical and health sciences ,Sex Factors ,Internal medicine ,medicine ,Humans ,sex ,cardiovascular diseases ,Physical and Theoretical Chemistry ,Molecular Biology ,Pathological ,business.industry ,Organic Chemistry ,ventricular arrhythmias ,Arrhythmias, Cardiac ,QT ,Androgen ,medicine.disease ,anticancer drugs ,lcsh:Biology (General) ,lcsh:QD1-999 ,business ,Homeostasis ,Hormone - Abstract
International audience; Significant variations from the normal QT interval range of 350 to 450 milliseconds (ms) in men and 360 to 460 ms in women increase the risk for ventricular arrhythmias. This difference in the QT interval between men and women has led to the understanding of the influence of sex hormones on the role of gender-specific channelopathies and development of ventricular arrhythmias. The QT interval, which represents the duration of ventricular repolarization of the heart, can be affected by androgen levels, resulting in a sex-specific predilection for acquired and inherited channelopathies such as acquired long QT syndrome in women and Brugada syndrome and early repolarization syndrome in men. Manipulation of the homeostasis of these sex hormones as either hormonal therapy for certain cancers, recreational therapy or family planning and in transgender treatment has also been shown to affect QT interval duration and increase the risk for ventricular arrhythmias. In this review, we highlight the effects of endogenous and exogenous sex hormones in the physiological and pathological states on QTc variation and predisposition to gender-specific pro-arrhythmias.
- Published
- 2021
10. Immune Checkpoint Inhibitor‐Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis
- Author
-
Melissa Y.Y. Moey, Joe-Elie Salem, Bénédicte Lebrun-Vignes, Javid Moslehi, Virginie Grouthier, Anne Bachelot, Douglas B. Johnson, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de pharmacologie médicale [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de référence des maladies endocriniennes rares de la croissance et du développement [CHU Pitié-Salpêtrière], Service de Pharmacologie médicale [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases [IHU ICAN], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), and Gestionnaire, Hal Sorbonne Université
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,[SDV]Life Sciences [q-bio] ,030209 endocrinology & metabolism ,Ipilimumab ,Pembrolizumab ,World Health Organization ,Primary Adrenal Insufficiency ,03 medical and health sciences ,Immune checkpoint inhibitors ,Antineoplastic Agents, Immunological ,0302 clinical medicine ,Addison Disease ,Immune-related adverse events ,Internal medicine ,Pharmacovigilance ,medicine ,Adrenal insufficiency ,Humans ,Adverse effect ,Aged ,Aged, 80 and over ,business.industry ,Endocrine toxicity ,Middle Aged ,medicine.disease ,Immuno‐Oncology ,3. Good health ,[SDV] Life Sciences [q-bio] ,Clinical trial ,Oncology ,030220 oncology & carcinogenesis ,Immunotherapy ,Nivolumab ,Primary adrenal insufficiency ,business ,Adrenal Insufficiency ,medicine.drug - Abstract
Background Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may also trigger autoimmune adverse drug reactions (ADRs) referred to as immune-related adverse events (irAEs). Although endocrinopathies are among the most common form of irAEs, primary adrenal insufficiency (PAI) is infrequent and has only been published in case reports. The aim of this study was to identify and characterize the main features of PAI-irAE. Materials and Methods Suspected PAI-irAE cases were identified using VigiBase, the World Health Organization's pharmacovigilance database of individual case safety reports. Results From September 2, 2008, through October 5, 2018, a total of 50,108 ICI-associated ADRs were reported. Since 2008, there were 451 cases of PAI-irAE identified of which 45 were “definite PAI” and 406 “possible PAI.” Patients were mainly male (58.1%) with a median age of 66 years (range, 30–95). Indications of ICI were predominantly for melanoma (41.2%) and lung cancer (28.6%). The majority of patients were treated with ICI monotherapy (nivolumab: 44.3%, pembrolizumab: 11.7%, ipilimumab: 23.6%), and 17.9% were treated with ICI combination therapy. These events occurred with a median time to onset of 120 days (range, 6–576). ICI-associated PAI was associated with significant morbidity (≥90% severe) and mortality (7.3%). Fatality rates were similar in the subgroups of combination therapy versus monotherapy. There were no relevant differences in clinical or demographical characteristics and outcomes between “definite” versus “possible” PAI group. Conclusion Our study represents the largest clinical description and characterization of PAI-irAE. Although ICI-associated PAI is a rare adverse event, early recognition is important to implement corticosteroid treatment. Further studies are required to elucidate risk factors and reversibility of this rare but severe irAE. Clinical trial identification number. NCT03492242 Implications for Practice Immune checkpoint inhibitor (ICI)-associated primary adrenal insufficiency (PAI) is a rare adverse event that is important to recognize because it may be severe and life-threatening, requiring emergent and often lifelong hormonal replacement therapy. Awareness regarding this ICI-related endocrinopathy is strongly encouraged among clinicians in addition to patient education about common PAI symptoms that should prompt urgent medical evaluation. In clinical practice, close monitoring and investigation for PAI is crucial to allow for early management and to further define the pathophysiology and prognosis of ICI-PAI. Corticotrophin (adrenocorticotrophic hormone) circulating level evaluation may be often lacking but should be considered as part of the diagnostic workup to differentiate PAI from secondary (central) adrenal insufficiency.
- Published
- 2020
11. Positive association between progestins and the evolution of multiple fibroadenomas in 72 women
- Author
-
Zeina Chakhtoura, Yasmina Badachi, Vincent Goffin, Isabelle Tejedor, Virginie Grouthier, and Philippe Touraine
- Subjects
Longitudinal study ,medicine.medical_specialty ,medicine.drug_class ,breastfeeding ,Endocrinology, Diabetes and Metabolism ,Disease ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Breast cancer ,Internal Medicine ,medicine ,Breast ultrasound ,Pregnancy ,lcsh:RC648-665 ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Obstetrics ,business.industry ,Research ,medicine.disease ,Lynestrenol ,contraception ,progestins ,030220 oncology & carcinogenesis ,Cohort ,fibroadenomas ,pregnancy ,business ,Progestin ,medicine.drug - Abstract
Objective Multiple fibroadenomas (MFA) of the breast is a rare benign disease, thus its natural history is poorly understood. The aim of our study was to describe the radiological evolution of MFA and to evaluate the influence of different factors on this evolution. Methods This was a longitudinal cohort study. All patients included had two clinical and radiological assessments (breast ultrasound (US) and/or MRI) at least 5 years apart. Results Seventy-two women were followed for 7.6 ± 2.1 years. The radiological evolution showed a decrease or stability in the number of fibroadenomas (FA) in 26/44 cases on the MRI and in 38/64 cases on the US. There was a decrease of size in 35/44 cases on the MRI and in 53/64 cases on the US. An increase in the number of FAs was found in 18/44 cases in the MRI and 26/64 cases in the US with, for the majority, a decrease of size (19/26 by MRI and 16/18 by MRI). Older age at the first FA (P < 0.0001) and at the diagnosis of MFA (P < 0.0001), pregnancy (P = 0.003) and progestin use (P < 0.001), particularly lynestrenol (P < 0.0001), had a beneficial effect on the evolution of MFA. Conclusion This is the first longitudinal study describing women with MFA. The radiological evolution of MFA seamed favorable and similar to that expected for a single FA. We identified factors influencing the evolution of the disease, including progestin treatments such as lynestrenol, which could have a beneficial effect. Our cohort should be followed further in order to expand our knowledge of MFA, especially concerning the risk of breast cancer.
- Published
- 2020
12. Response to Comment on Foussard et al. Skin Autofluorescence of Pregnant Women With Diabetes Predicts the Macrosomia of Their Children. Diabetes 2019;68:1663-1669
- Author
-
Laurence Blanco, Kamel Mohammedi, Laure Alexandre, Thierry Lamireau, Ninon Foussard, Cécile Delcourt, Magalie Haissaguerre, Vincent Rigalleau, C. Gonzalez, Catherine Helmer, Kalina Rajaobelina, Virginie Grouthier, and Audrey Cougnard-Gregoire
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Pregnancy in Diabetics ,030209 endocrinology & metabolism ,Weight Gain ,Fetal Macrosomia ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Diabetes mellitus ,Internal Medicine ,medicine ,Fetal macrosomia ,Humans ,Child ,Obstetrics ,business.industry ,Skin autofluorescence ,medicine.disease ,Pregnancy Complications ,Diabetes, Gestational ,030104 developmental biology ,Gestation ,Female ,medicine.symptom ,business ,Weight gain - Abstract
We were interested in the comment from Cosson et al. (1) on our recent report about high skin autofluorescence (sAF) in hyperglycemic mothers of large-for-gestational-age (LGA) newborns (2). Several reasons can explain why Cosson et al., and previously de Ranitz-Greven et al. (3), failed to detect a relationship between sAF and macrosomia. The first explanation is the low number of participants, 100 in de Ranitz-Greven et al. (3) and 148 in Cosson et al. (1), which can lead to an underpowered study and a lack of statistical power, versus 343 …
- Published
- 2020
13. Assessment of vertebral microarchitecture in overt and mild Cushing's syndrome using trabecular bone score
- Author
-
Renaud Winzenrieth, Nadia Mehsen-Cetre, Amandine Boisson, Virginie Grouthier, Helene Vinolas, Charles Mesguich, Antoine Tabarin, Laurence Bordenave, and Thierry Schaeverbeke
- Subjects
0301 basic medicine ,Cortisol secretion ,medicine.medical_specialty ,S syndrome ,business.industry ,Endocrinology, Diabetes and Metabolism ,Osteoporosis ,Urology ,030209 endocrinology & metabolism ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Endocrinology ,Normal bone ,Trabecular bone score ,Internal medicine ,Macronodular Adrenal Hyperplasia ,medicine ,Etiology ,business ,Mace - Abstract
OBJECTIVE Osteoporotic fractures associated with Cushing's syndrome (CS) may occur despite normal bone mineral density (BMD). Few studies have described alterations in vertebral microarchitecture in glucocorticoid-treated patients and during CS. Trabecular bone score (TBS) estimates trabecular microarchitecture from dual-energy X-ray absorptiometry acquisitions. Our aim was to compare vertebral BMD and TBS in patients with overt CS and mild autonomous cortisol secretion (MACE), and following cure of overt CS. SETTING University Hospital. DESIGN Monocentric retrospective cross-sectional and longitudinal studies of consecutive patients. PATIENTS A total of 110 patients were studied: 53 patients had CS (35, 11 and 7 patients with Cushing's disease, bilateral macronodular adrenal hyperplasia and ectopic ACTH secretion respectively); 39 patients had MACE (10 patients with a late post-operative recurrence of Cushing's disease and 29 patients with adrenal incidentalomas); 18 patients with non-secreting adrenal incidentalomas. 14 patients with overt CS were followed for up to 2 years after cure. RESULTS Vertebral osteoporosis at BMD and degraded microarchitecture at TBS were found in 24% and 43% of patients with CS, respectively (P
- Published
- 2018
14. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors
- Author
-
Dan M. Roden, Andrew M. Glazer, Joe-Elie Salem, Anne Bachelot, Carine Courtillot, Javid Moslehi, Bénédicte Lebrun-Vignes, Antoine Pariente, Christian Funck-Brentano, Philippe Touraine, Virginie Grouthier, Centre de référence des maladies endocriniennes rares de la croissance et du développement [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d’endocrinologie et médecine de la reproduction [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Vanderbilt University [Nashville], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Pierre et Marie Curie - Paris 6 (UPMC)
- Subjects
Oncology ,Databases, Factual ,[SDV]Life Sciences [q-bio] ,Action Potentials ,030204 cardiovascular system & hematology ,chemistry.chemical_compound ,0302 clinical medicine ,Exemestane ,Heart Rate ,Risk Factors ,Torsades de Pointes ,Aged, 80 and over ,Aromatase Inhibitors ,Letrozole ,Middle Aged ,Prognosis ,3. Good health ,Europe ,Long QT Syndrome ,030220 oncology & carcinogenesis ,Female ,Cardiology and Cardiovascular Medicine ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug ,Adult ,Selective Estrogen Receptor Modulators ,medicine.medical_specialty ,Adolescent ,Long QT syndrome ,Anastrozole ,Torsades de pointes ,Risk Assessment ,QT interval ,Article ,Young Adult ,03 medical and health sciences ,Heart Conduction System ,Internal medicine ,medicine ,Adverse Drug Reaction Reporting Systems ,Humans ,cardiovascular diseases ,Aged ,business.industry ,ventricular arrhythmias ,medicine.disease ,Cardiotoxicity ,Tamoxifen ,chemistry ,sex steroid hormones ,torsade de pointes ,business ,Adverse drug reaction - Abstract
ObjectiveA prolonged QTc (LQT) is a surrogate for the risk of torsade de pointes (TdP). QTc interval duration is influenced by sex hormones: oestradiol prolongs and testosterone shortens QTc. Drugs used in the treatment of breast cancer have divergent effects on hormonal status.MethodsWe performed a disproportionality analysis using the European database of suspected adverse drug reaction (ADR) reports to evaluate the reporting OR (ROR χ2) of LQT, TdP and ventricular arrhythmias associated with selective oestrogen receptor modulators (SERMs: tamoxifen and toremifene) as opposed to aromatase inhibitors (AIs: anastrozole, exemestane and letrozole). When the proportion of an ADR is greater in patients exposed to a drug (SERMs) compared with patients exposed to control drug (AIs), this suggests an association between the specific drug and the reaction and is a potential signal for safety. Clinical and demographic characterisation of patients with SERMs-induced LQT and ventricular arrhythmias was performed.ResultsSERMs were associated with higher proportion of LQT reports versus AIs (26/8318 vs 11/14851, ROR: 4.2 (2.11–8.55), pConclusionsSERMs are associated with more reports of drug-induced LQT, TdP and ventricular arrhythmias compared with AIs. This finding is consistent with oestradiol-like properties of SERMs on the heart as opposed to effects of oestrogen deprivation and testosterone increase induced by AIs.Trial registration numberNCT03259711.
- Published
- 2018
15. MANAGEMENT OF ENDOCRINE DISEASE: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: update on the management of adult patients and prenatal treatment
- Author
-
Virginie Grouthier, Anne Bachelot, Carine Courtillot, Jérôme Dulon, and Philippe Touraine
- Subjects
medicine.medical_specialty ,Hormone Replacement Therapy ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Disease ,Androgen Excess ,Dexamethasone ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Congenital adrenal hyperplasia due to 21-hydroxylase deficiency ,Risk Factors ,Internal medicine ,medicine ,Humans ,Congenital adrenal hyperplasia ,Glucocorticoids ,Endocrine disease ,Adrenal Hyperplasia, Congenital ,business.industry ,Disease Management ,Hormone replacement therapy (menopause) ,General Medicine ,medicine.disease ,3. Good health ,030220 oncology & carcinogenesis ,business ,Glucocorticoid ,medicine.drug - Abstract
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is characterized by cortisol and in some cases aldosterone deficiency associated with androgen excess. Goals of treatment are to replace deficient hormones and control androgen excess, while avoiding the adverse effects of exogenous glucocorticoid. Over the last 5 years, cohorts of adults with CAH due to 21-hydroxylase deficiency from Europe and the United States have been described, allowing us to have a better knowledge of long-term complications of the disease and its treatment. Patients with CAH have increased mortality, morbidity and risk for infertility and metabolic disorders. These comorbidities are due in part to the drawbacks of the currently available glucocorticoid therapy. Consequently, novel therapies are being developed and studied in an attempt to improve patient outcomes. New management strategies in the care of pregnancies at risk for congenital adrenal hyperplasia using fetal sex determination and dexamethasone have also been described, but remain a subject of debate. We focused the present overview on the data published in the last 5 years, concentrating on studies dealing with cardiovascular risk, fertility, treatment and prenatal management in adults with classic CAH to provide the reader with an updated review on this rapidly evolving field of knowledge.
- Published
- 2017
16. Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk
- Author
-
Rémi Pierre, Isabelle Tejedor, Aurélie Chiche, Zeina Chakhtoura, Carine Courtillot, Florence Boutillon, P. Camparo, Fabienne Rakotozafy, Vincent Goffin, Natascha Pigat, Jacques-Emmanuel Guidotti, Marie-Laure Tanguy, Sophie Vacher, Fatima Laki, Anne Bissery, Ivan Bièche, Marc Foretz, Marie Bernadet, Jean Tichet, Virginie Grouthier, Philippe Touraine, Sophie Bernichtein, Marcio Do Cruzeiro, Brigitte Sigal-Zafrani, and Ibtissem Cherifi
- Subjects
Adult ,0301 basic medicine ,Genetically modified mouse ,medicine.medical_specialty ,Adolescent ,Receptors, Prolactin ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Breast Neoplasms ,Mice, Transgenic ,Context (language use) ,Biochemistry ,Germline ,Cohort Studies ,Mice ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Breast cancer ,Breast Fibroadenoma ,Internal medicine ,medicine ,Animals ,Humans ,business.industry ,Prolactin receptor ,Biochemistry (medical) ,Middle Aged ,medicine.disease ,Fibroadenoma ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,030220 oncology & carcinogenesis ,Cohort ,Female ,business - Abstract
In a cohort of 95 women with multiple breast fibroadenomas (MFAs), we recently identified patients harboring germline heterozygous variants of the prolactin receptor (PRLR) exhibiting constitutive activity (PRLRThis study sought to better delineate the potential role of PRLR gain-of-function variants in benign and malignant mammary tumorigenesis.This was an observational study and transgenic mouse model analysis.The study took place at the Department of Endocrinology, Reproductive Disorders and Rare Gynecologic Diseases, Pitié Salpêtrière, Paris, and Inserm Unit 1151, Paris.We generated a second MFA cohort (n = 71) as well as a group of control subjects (n = 496) and a cohort of women with breast cancer (n = 119). We also generated two transgenic mouse models carrying the coding sequences of human PRLRWe aimed to determine the prevalence of PRLR variants in these three populations and to uncover any association of the latter with specific tumor pattern, especially in patients with breast cancer.This study did not highlight a higher prevalence of PRLR variants in the MFA group and in the breast cancer group compared with control subjects. Transgenic mice expressing PRLRPRLR
- Published
- 2016
17. Why might pumps fail in pregnant women with Type 1 diabetes?
- Author
-
Magalie Haissaguerre, Fritz-Line Vélayoudom-Céphise, Laurence Blanco, Ninon Foussard, Marie Monlun, Pauline Poupon, Claire Ducos, Sophie Cambos, Kamel Mohammedi, Vincent Rigalleau, Virginie Grouthier, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,MEDLINE ,Pregnancy in Diabetics ,030209 endocrinology & metabolism ,LEHA ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Insulin Infusion Systems ,Pregnancy ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Insulin ,030212 general & internal medicine ,Type 1 diabetes ,business.industry ,Infant, Newborn ,medicine.disease ,Gestational Weight Gain ,Diabetes Mellitus, Type 1 ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Female ,business - Published
- 2019
18. Hyperandrogénie d'origine ovarienne
- Author
-
Philippe Touraine and Virginie Grouthier
- Published
- 2019
19. Management of Adult Patients With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
- Author
-
Virginie Grouthier, Jérôme Dulon, Anne Bachelot, and Philippe Touraine
- Published
- 2019
20. Fertility and Pregnancy in Patients With 21-Hydroxylase Deficiency
- Author
-
Virginie Grouthier, Philippe Touraine, Jérôme Dulon, Anne Bachelot, and Carine Courtillot
- Subjects
Pregnancy ,biology ,medicine.drug_class ,business.industry ,Virilization ,media_common.quotation_subject ,Genetic counseling ,21-Hydroxylase ,Physiology ,Fertility ,medicine.disease ,Androgen ,medicine ,biology.protein ,Congenital adrenal hyperplasia ,medicine.symptom ,business ,Dexamethasone ,media_common ,medicine.drug - Abstract
21-Hydroxylase deficiency (21OHD) is the most common cause of congenital adrenal hyperplasia. Sexuality and fertility in women with classic 21OHD is impaired, due to several issues such as disrupted gonadotropic axis due to androgen and progesterone overproduction, and mechanical, psychological factors related to genital surgery. Fertility and fecundity in these women gets better over the years. Subfertility seems contrariwise to be relative in nonclassic CAH women. Before pregnancy, genotyping the partner and genetic counseling is mandatory. The use of dexamethasone during pregnancy in order to prevent the virilization of the young affected CAH girl remains a matter of debate.
- Published
- 2019
21. Is skin autofluorescence a marker of metabolic memory in pregnant women with diabetes?
- Author
-
Kalina Rajaobelina, Pascale Barberger-Gateau, H. Gin, C. Gonzalez, L. Corvo, S. Lorrain, Virginie Grouthier, Vincent Rigalleau, E. Maury, and J. Savel
- Subjects
Adult ,Glycation End Products, Advanced ,Risk ,medicine.medical_specialty ,Pregnancy Trimester, Third ,Endocrinology, Diabetes and Metabolism ,Pregnancy in Diabetics ,Type 2 diabetes ,Fluorescence ,chemistry.chemical_compound ,Endocrinology ,Pregnancy ,Recurrence ,Diabetes mellitus ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Skin ,Glycated Hemoglobin ,business.industry ,Obstetrics ,Skin autofluorescence ,medicine.disease ,Up-Regulation ,Gestational diabetes ,Diabetes, Gestational ,Forearm ,Autofluorescence ,Diabetes Mellitus, Type 1 ,Spectrometry, Fluorescence ,Diabetes Mellitus, Type 2 ,chemistry ,Pregnancy Trimester, Second ,Fructosamine ,Gestation ,Advanced glycation end-product ,Female ,France ,business ,Biomarkers - Abstract
Aim To determine whether skin autofluorescence can help to detect those who have previously had abnormal glucose levels among women referred for diabetes during pregnancy. Methods Using an advanced glycation end product reader (AGE Readertm; DiagnOptics BV, Groningen, the Netherlands), we measured forearm skin autofluorescence at 24–30 weeks of gestation in all women who were referred to our Nutrition Diabetology unit for diabetes during pregnancy. Results The study included 230 women (200 with gestational diabetes and 30 with pre-gestational diabetes, of whom 21 had Type 1 and nine had Type 2 diabetes) and a reference group of 22 normoglycaemic non-pregnant women. Skin autofluorescence was significantly higher in women with pre-gestational diabetes (1.97 ± 0.44 arbitary units) compared with gestational diabetes (1.77 ± 0.32 arbitary units; P = 0.003) and lower in the reference group (1.60 ± 0.32 arbitary units; P = 0.009 vs all pregnant women). Among women with gestational diabetes, 71 had a history of hyperglycaemia (i.e. gestational diabetes or macrosomia in a previous pregnancy or discovery of diabetes before 24th gestational week in the present pregnancy). These women had higher levels of skin autofluorescence (1.83 ± 0.35 arbitary units) than women with gestational diabetes without previous history of hyperglycaemia (1.73 ± 0.30 arbitary units; P = 0.04, non-significant, adjusted for age). Skin autofluorescence increased with the number of criteria present for previous hyperglycaemia (P for trend = 0.008) and was significantly associated with having two or three criteria for hyperglycaemia after adjusting for age (P = 0.02). Conclusions Skin autofluorescence could reflect previous long-term hyperglycaemia in pregnant women, and could therefore be a marker of metabolic memory.
- Published
- 2015
22. Comment on Law et al. Suboptimal Nocturnal Glucose Control Is Associated With Large for Gestational Age in Treated Gestational Diabetes Mellitus. Diabetes Care 2019;42:810–815
- Author
-
Laurence Blanco, Virginie Grouthier, Magalie Haissaguerre, Fritz-Line Vélayoudom-Céphise, Vincent Rigalleau, Pauline Poupon, Ninon Foussard, Sophie Cambos, Kamel Mohammedi, and Marie Monlun
- Subjects
Advanced and Specialized Nursing ,Pregnancy ,Glucose tolerance test ,endocrine system diseases ,Glucose control ,medicine.diagnostic_test ,business.industry ,Endocrinology, Diabetes and Metabolism ,nutritional and metabolic diseases ,Gestational age ,030209 endocrinology & metabolism ,Nocturnal ,medicine.disease ,Gestational diabetes ,03 medical and health sciences ,0302 clinical medicine ,Law ,Diabetes mellitus ,Internal Medicine ,medicine ,Gestation ,030212 general & internal medicine ,business - Abstract
We were interested in the article by Law et al. (1), who reported that high nocturnal glucose, as recorded by continuous glucose monitoring (CGM), was associated with large for gestational age (LGA) newborns in women with gestational diabetes mellitus (GDM). The nocturnal hyperglycemia was not detected by fasting self-monitored blood glucose (SMBG), which argues for performing CGM in GDM. The figure in the article nicely depicts how nocturnal hyperglycemia was missed by conventional SMBG: as underlined by the authors, the difference in nocturnal CGM glucose between mothers of LGA infants and those of normal-weight newborns was a peak displayed at 0200–0300 h, which then progressively declined to become nonsignificant when the women …
- Published
- 2019
23. Inversion péricentrique d’un chromosome 7 associée à une insuffisance ovarienne prématurée et une maladie inflammatoire chronique de l’intestin : 2 points de cassure pour 2 symptômes ?
- Author
-
Jean-Pierre Siffroi, Sylvie Lucchini, Capucine Hyon, Isabelle Pinson, Virginie Grouthier, and Patricia Dournaux
- Subjects
03 medical and health sciences ,030219 obstetrics & reproductive medicine ,0302 clinical medicine ,Anatomy ,030226 pharmacology & pharmacy - Abstract
Objet Une cause genetique de l’insuffisance ovarienne prematuree (IOP) est retrouvee dans 20 a 25 % des IOP [1] . Les anomalies cytogenetiques (10 a 13 %) concernent le plus souvent le chromosome X mais des remaniements des autosomes sont egalement possibles. Methodes Etude en cytogenetique classique et moleculaire d’une patiente adressee pour IOP a l’âge de 38 ans et qui presente egalement une maladie inflammatoire chronique de l’intestin (MICI) de type rectocolite hemorragique (RCH) et un asthme. Le pere et la grand-mere paternelle presentent egalement une MICI de type maladie de Crohn (MC). Resultats Presence d’une inversion pericentrique du chromosome 7 : 46,XX, inv(7)(p14q21.1).ish inv(7)(p14q21.1)(wcp7 + ,LSI ELN + ,D7Z1 + ,RP5-998H4 + ,TelVysion 7q + ). Discussion Le point de cassure sur le bras court est situe dans la bande p14 qui contient le gene PTHB1. Kang et al. en 2008 ont montre dans une etude d’association de genome (GWAS), l’implication de PTHB1 comme facteur de susceptibilite dans les IOP [2] . Par ailleurs, le point de cassure sur le bras long est contenu dans un intervalle de 15Mb qui contient le gene ABCB1 qui a ete propose comme gene candidat dans les MICI [3] et dont l’expression est diminuee dans les cas de MICI [4] . Une interruption de ces genes ou de leurs regions regulatrices pourrait expliquer le phenotype presente par la patiente. Afin de completer cette etude, un clonage des points de cassure et une etude en ACPA (analyse chromosomique sur puce a ADN) pour confirmer le caractere equilibre du remaniement sont prevus. Par ailleurs, le caryotype des parents va egalement etre realise pour rechercher une origine familiale de ce remaniement en particulier chez le pere qui presente egalement une MICI. Conclusion Nous rapportons le cas d’une patiente presentant une IOP et une MICI avec une inversion pericentrique d’un chromosome 7 qui pourrait expliquer l’ensemble des symptomes presentes par la patiente.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.